Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 15, 2024
Daily News
February 15, 2024
- Japan to Ponder New COVID Vaccine Composition from Spring
February 15, 2024
- Payers, HCPs Hail First Step Taken for Generic Industry Revamp in FY2024 Reform
February 15, 2024
- Ono Strikes New Oncology Pact with Numab
February 15, 2024
- Takeda Files Immunoglobulin Hyqvia in Japan
February 15, 2024
- Otsuka’s 2023 Pharma Sales Climb 20% on 4 Global Brands
February 15, 2024
- KOL Highlights Need for Further RSV Epidemiological Research in Japan
February 15, 2024
- GSK Japan Nets 11% Sales Rise in 2023, Sees 6% CAGR through 2026: President
February 15, 2024
- Japan to Announce New Drug Prices on March 5
February 15, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…